The report evaluated 15 of the largest commercial formularies for prescription drugs in the U.S. to determine how they matched fair access criteria developed by ICER.

A new report attempts to pierce the veil of drug pricing and insurance coverage, an area that is marked by a lack of industry data and a surfeit of horror stories from consumers. Overall, the report noted the limitations of its conclusions but found that most payers seemed to be providing fair access for the drugs in the analysis, based on the available data.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.